Cited by 28

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Hepatic Overexpression of Idol Increases Circulating Protein Convertase Subtilisin/Kexin Type 9 in Mice and Hamsters via Dual Mechanisms: Sterol Regulatory Element–Binding Protein 2 and Low-Density Lipoprotein Receptor–Dependent Pathways

Sasaki, Makoto, Terao, Yoshio, Ayaori, Makoto, Uto-Kondo, Harumi, Iizuka, Maki, Yogo, Makiko, Hagisawa, Kosuke, Takiguchi, Shunichi, Yakushiji, Emi, Nakaya, Kazuhiro, Ogura, Masatsune, Komatsu, Tomohiro, Ikewaki, Katsunori·2014·Arteriosclerosis, Thrombosis, and Vascular Biology

Abstract

Objective—: Low-density lipoprotein receptor (LDLR) is degraded by inducible degrader of LDLR (Idol) and protein convertase subtilisin/kexin type 9 (PCSK9), thereby regulating circulating LDL levels. However, it remains unclear whether, and if so how, these LDLR degraders affect each other. We therefore investigated effects of liver-specific expression of Idol on LDL/PCSK9 metabolism in mice and hamsters. Approach and Results—: Injection of adenoviral vector expressing Idol (Ad-Idol) induced a liver-specific reduction in LDLR expression which, in turn, increased very-low-density lipoprotein/LDL cholesterol levels in wild-type mice because of delayed LDL catabolism. Interestingly, hepatic Idol overexpression markedly increased plasma PCSK9 levels. In LDLR-deficient mice, plasma PCSK9 levels were already elevated at baseline and unchanged by Idol overexpression, which was comparable with the observation for Ad-Idol–injected wild-type mice, indicating that Idol-induced PCSK9 elevation depended on LDLR. In wild-type mice, but not in LDLR-deficient mice, Ad-Idol enhanced hepatic PCSK9 expression, with activation of sterol regulatory element–binding protein 2 and subsequently increased expression of its target genes. Supporting in vivo findings, Idol transactivated PCSK9/LDLR in sterol regulatory element–binding protein 2/LDLR-dependent manners in vitro. Furthermore, an in vivo kinetic study using 125 I-labeled PCSK9 revealed delayed clearance of circulating PCSK9, which could be another mechanism. Finally, to extend these findings into cholesteryl ester transfer protein–expressing animals, we repeated the above in vivo experiments in hamsters and obtained similar results. Conclusions—: A vicious cycle in LDLR degradation might be generated by PCSK9 induced by hepatic Idol overexpression via dual mechanisms: sterol regulatory element–binding protein 2/LDLR. Furthermore, these effects would be independent of cholesteryl ester transfer protein expression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/atvbaha.113.302670

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Increased IDOL-mediated degradation of the LDLR likely explains why secreted PCSK9 accumulates in MARCH6-silenced cells; decreased LDLR prevents clearance of PCSK9 via the LDLR pathway.

    “Increased IDOL-mediated degradation of the LDLR also likely explains why secreted PCSK9 accumulates in MARCH6-silenced cells; decreased LDLR prevents clearance of PCSK9 via the LDLR pathway, as also suggested previously (41).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 21

  1. 10.1016/0002-9149(87)90585-6 · DOI
  2. 10.1073/pnas.76.7.3330 · DOI · Paper page
  3. 10.1016/j.cell.2005.12.022 · DOI · Paper page
  4. 10.1038/ng1161 · DOI · Paper page
  5. 10.1056/NEJMoa054013 · DOI · Paper page
  6. 10.1126/science.1168974 · DOI · Paper page
  7. 10.5551/jat.11.110 · DOI
  8. 10.1172/JCI118196 · DOI
  9. 10.1172/JCI116750 · DOI
  10. 10.1016/S0021-9258(19)74263-X · DOI
  11. 10.1161/circulationaha.113.001592 · DOI · Paper page
  12. 10.1194/jlr.M800027-JLR200 · DOI · Paper page
  13. 10.1161/01.atv.0000134621.14315.43 · DOI · Paper page
  14. 10.1194/jlr.M700437-JLR200 · DOI
  15. 10.1161/JAHA.112.000028 · DOI
  16. Weber A, Wasiliew P, Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal. 2010;3:cm1.
  17. 10.1161/circresaha.110.226878 · DOI
  18. 10.1016/j.bbalip.2011.08.009 · DOI
  19. 10.1073/pnas.0712064105 · DOI · Paper page
  20. 10.1073/pnas.0806312105 · DOI · Paper page
  21. 10.1128/MCB.01469-10 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Sasaki, M., Terao, Y., Ayaori, M., Uto-Kondo, H., Iizuka, M., Yogo, M., Hagisawa, K., Takiguchi, S., Yakushiji, E., Nakaya, K., Ogura, M., Komatsu, T., & Ikewaki, K.
Affiliations
From the Division of Anti-aging and Vascular Medicine, Department of Internal Medicine (M.S., Y.T., M.A., H.U.-K., M.I., M.Y., S.T., E.Y., K.N., M.O., T.K., K.I.) and Department of Physiology (K.H.), National Defense Medical College, Tokorozawa, Japan.
Venue
Arteriosclerosis, Thrombosis, and Vascular Biology
Published
2014-06
Volume
34
Issue
6
Pages
1171-1178
ISSN
  • 1079-5642
  • 1524-4636
Cited by
28
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review